Chronic Obstructive Pulmonary Disease Case Finding in Community-pharmacies by Spirometry (FARMAEPOC)
Chronic Obstructive Pulmonary Disease (COPD) is a prevalent disease. In the investigators country, underdiagnosis has been estimated in around 80% of subjects. Early detection is done mainly in primary care but due to actual situation new alternatives have been proposed to decrease underdiagnosis.
This present study promote by a multidisciplinary research team (respiratory medicine, primary care, nurse and pharmacist) raise the objective of evaluate the effect of a COPD case finding program guide by spirometry in community-pharmacies.
From the results of a pilot-study conducted in 13 community-pharmacies in Barcelona, in which the investigators showed the feasibility of spirometry in community-pharmacies for the early detection of COPD, the investigators have design a second phase to evaluate the effect of this strategy. 100 Barcelona's community-pharmacies during 6 months will select high risk customers and will conduct a spirometry in agreement with the design protocol. 3600 spirometries is the establish objective. Participants hospitals will train pharmacist in spirometry and also control spirometry quality daily by a telematic pathway. Spirometry results will be evaluate in terms of effect and costs. The investigators will also evaluate the impact of this program in the health system by numbers of subjects diagnosed and follow up in primary care.
|Study Design:||Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Screening
|Official Title:||Efficiency of COPD Case Finding Program by Spirometry in High-risk Customers of Urban Community Pharmacies|
- COPD Case Finding [ Time Frame: During 15 months pharmacies will include subjects with possible COPD through spirometry. ]Proportion of high-risk customers with spirometry showing a FEV1/FVC under 0,7.
|Study Start Date:||October 2010|
|Estimated Study Completion Date:||June 2013|
|Estimated Primary Completion Date:||July 2012 (Final data collection date for primary outcome measure)|
High Risk Customers
Pharmacy customers with GOLD COPD Criteria of high-risk subjects.
Spirometry done in high-risk customers of community-pharmacies to detect airflow limitation
Please refer to this study by its ClinicalTrials.gov identifier: NCT01576068
|Col·legi Oficial de Farmacèutics de Barcelona|
|Barcelona, Spain, 08009|
|Principal Investigator:||Diego Castillo, MD||Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau|